Cabiralizumab
Cabiralizumab (pronunciation: ka-bi-ra-li-zu-mab) is a monoclonal antibody designed for the treatment of cancer. It is developed by Bristol-Myers Squibb and is currently in clinical trials.
Etymology
The name "Cabiralizumab" is derived from the standard nomenclature for monoclonal antibodies. The "-mab" suffix indicates that it is a monoclonal antibody, while the "-lizu-" infix suggests that it is a humanized antibody. The prefix "Cabira-" does not have a specific meaning and is likely a proprietary designation by the manufacturer.
Mechanism of Action
Cabiralizumab works by inhibiting the Colony Stimulating Factor 1 Receptor (CSF1R), a protein that plays a crucial role in the survival, proliferation, and differentiation of monocytes and macrophages. By blocking this receptor, Cabiralizumab can help to reduce the number of tumor-associated macrophages (TAMs) in the tumor microenvironment, which can potentially slow down tumor growth and spread.
Clinical Trials
Cabiralizumab is currently being tested in several clinical trials for its efficacy and safety in treating various types of cancer, including pancreatic cancer, melanoma, and non-small cell lung cancer (NSCLC).
Related Terms
- Monoclonal Antibody
- Bristol-Myers Squibb
- Colony Stimulating Factor 1 Receptor (CSF1R)
- Monocytes
- Macrophages
- Tumor-associated macrophages (TAMs)
- Clinical Trials
- Pancreatic Cancer
- Melanoma
- Non-small cell lung cancer (NSCLC)
External links
- Medical encyclopedia article on Cabiralizumab
- Wikipedia's article - Cabiralizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski